BC
HZNP

Bartlett & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bartlett & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-68,882
Closed -$7.97M – 1274
2023
Q3 		$7.97M Sell
68,882
-4,963
-7% -$533K 0.14% 106
2023
Q2 		$7.59M Buy
73,845
+66,345
+885% +$7M 0.13% 112
2023
Q1 		$819K Hold
7,500
– – 0.02% 243
2022
Q4 		$854K Sell
7,500
-2,500
-25% -$208K 0.02% 239
2022
Q3 		$619K Hold
10,000
– – 0.01% 254
2022
Q2 		$798K Sell
10,000
-1,386
-12% -$131K 0.02% 238
2022
Q1 		$1.2M Buy
11,386
+386
+4% +$37.6K 0.02% 215
2021
Q4 		$1.19M Hold
11,000
– – 0.02% 220
2021
Q3 		$1.21M Buy
+11,000
New +$1.14M 0.02% 196

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bartlett & Co's HZNP Position: Q4 2023 in Review

Bartlett & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 68,882 shares — an estimated $7.97M sold.

Bartlett & Co first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $7.97M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bartlett & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bartlett & Co sold 68,882 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $7.97M.
  • Bartlett & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
  • Bartlett & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.97M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.